Healthcare
Live Price
Offline$354.89
+2.09% today
1Y Change
+144.25%
Window
Jun 25, 2025 → Jun 18, 2026
Coverage: 247 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Krystal Biotech, Inc. (KRYS) is a Healthcare stock with a market cap of $7.80B and listed on NASDAQ. The stock last traded around $354.89 and up 144.3% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +33.9%, EPS growth of +126.9%, a dividend yield of 0.0%. What stands out right now is revenue +33.9%, EPS +126.9%, free cash flow +58.5% with operating margin 41.5% and ROIC 13.1%. Valuation already assumes a fairly strong business story at P/E 37.4 and price/sales 20.0. Stock Foundry combines KRYS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KRYS
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KRYS Max Drawdown
-15.94%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for KRYS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$69.6M
+50.3% YoY
Free Cash Flow
-$116.3M
+24.3% YoY
Revenue Growth
+33.9%
EPS Growth
+126.9%
Gross Margin
92.6%
Net Margin
52.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 389M | 291M | 51M | 0 | 0 |
| Gross Profit | 360M | 270M | 48M | 0 | 0 |
| Operating Income | 161M | 66M | -110M | -145M | -68M |
| EBITDA | 168M | 110M | -91M | -117M | -66M |
| Net Income | 205M | 89M | 11M | -140M | -70M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 496M | 345M | 358M | 162M | 341M |
| Total Assets | 1.3B | 1.1B | 818M | 558M | 626M |
| Total Liabilities | 114M | 109M | 40M | 36M | 33M |
| Shareholder Equity | 1.2B | 946M | 779M | 522M | 594M |
| Total Debt | 9M | 7M | 8M | 9M | 8M |
| Net Debt | -487M | -338M | -350M | -153M | -333M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
48M
+52.3% YoY
Capital Expenditures
68M
-29.0% YoY
Free Cash Flow
116M
+24.3% YoY
Key ratios
Gross Margin
92.6%
Operating Margin
41.5%
Net Margin
52.6%
ROE
18.7%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.